Treatment

SEP-363856 matching placebo clinical trials

2 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
This study is testing a new medicine, SEP-363856, for adults with major depression who are already taking antidepressants. It aims to see if adding this new medicine helps improve symptoms and if it's safe to use.
For: Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.
Czechia · Bulgaria · Spain
Ongoing, recruitingPhase II and Phase III (Integrated)
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Patients with Schizophrenia, Followed by an Open-label Extension Phase
This study is looking at a new medicine called SEP-363856 for people who are currently experiencing severe symptoms of schizophrenia. We want to see if it helps reduce these symptoms and if it's safe to use. Some participants will get the new medicine, and others will get a dummy pill.
For: Acutely Psychotic Patients with Schizophrenia
Romania